FEATURED COMPANIES
- AstraZeneca
- Clovis Oncology
- F. Hoffmann-La Roche
- Spectrum Pharmaceuticals
- TESARO
1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
Ovarian cancer is the second most common gynecologic cancer, and the incidence of the disease has been increasing. The incidence of ovarian cancer increases with age, mainly due to the cell DNA damage associated with age as a result of biological processes or due to the exposure to risk factors. In terms of the incidence rate, ovarian cancer is the eighth-most commonly occurring malignancy in women and the eighteenth-most common cancer overall. Thus, the increase in the incidence of ovarian cancer is expected to drive the growth of the global ovarian cancer drugs market during the forecast period. The analysts have predicted that the ovarian cancer drugs market will register a CAGR of over 22% by 2023.
Market Overview
Increasing awareness of ovarian cancer
The increasing awareness of ovarian cancer among physicians and patients is expected to drive the growth of the market during the forecast period. This has led to increased awareness among healthcare workers regarding the symptoms of ovarian cancer and the options to manage the disease.
High cost of treatment
The treatment of ovarian cancer is costly and imposes a high economic burden on the national healthcare system and on individuals. Hence, even though cost-effective oral chemotherapy drugs are available for the treatment of ovarian cancer often they are not offered to Medicare patients due to the above regulation and patients need to spend significant out-of-pocket costs. Hence, the cost of the treatment is a significant challenge in the market.
For the detailed list of factors that will drive and challenge the growth of the ovarian cancer drugs market during the 2019-2023, view this report.
Competitive Landscape
The market appears to be moderately fragmented and with the presence of several companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Market Overview
Increasing awareness of ovarian cancer
The increasing awareness of ovarian cancer among physicians and patients is expected to drive the growth of the market during the forecast period. This has led to increased awareness among healthcare workers regarding the symptoms of ovarian cancer and the options to manage the disease.
High cost of treatment
The treatment of ovarian cancer is costly and imposes a high economic burden on the national healthcare system and on individuals. Hence, even though cost-effective oral chemotherapy drugs are available for the treatment of ovarian cancer often they are not offered to Medicare patients due to the above regulation and patients need to spend significant out-of-pocket costs. Hence, the cost of the treatment is a significant challenge in the market.
For the detailed list of factors that will drive and challenge the growth of the ovarian cancer drugs market during the 2019-2023, view this report.
Competitive Landscape
The market appears to be moderately fragmented and with the presence of several companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- AstraZeneca
- Clovis Oncology
- F. Hoffmann-La Roche
- Spectrum Pharmaceuticals
- TESARO
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 05: MARKET SIZING
PART 09: GEOGRAPHIC LANDSCAPE
List of Exhibits
Exhibit 01: Years in consideration
Exhibit 02: Global oncology therapeutics market
Exhibit 03: Segments of global oncology therapeutics market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Pipeline drugs in late-stage clinical trials
Exhibit 07: Market definition - Inclusions and exclusions checklist
Exhibit 08: Market size 2018
Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 11: Five forces analysis 2018
Exhibit 12: Five forces analysis 2023
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2018
Exhibit 19: Type - Market share 2018-2023 (%)
Exhibit 20: Comparison by type
Exhibit 21: Epithelial ovarian cancer - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Epithelial ovarian cancer - Year-over-year growth 2019-2023 (%)
Exhibit 23: Germ cell ovarian cancer - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Germ cell ovarian cancer - Year-over-year growth 2019-2023 (%)
Exhibit 25: Stromal cell ovarian cancer - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Stromal cell ovarian cancer - Year-over-year growth 2019-2023 (%)
Exhibit 27: Small cell ovarian cancer - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Small cell ovarian cancer - Year-over-year growth 2019-2023 (%)
Exhibit 29: Market opportunity by type
Exhibit 30: Customer landscape
Exhibit 31: Market share by geography 2018-2023 (%)
Exhibit 32: Geographic comparison
Exhibit 33: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: North America - Year-over-year growth 2019-2023 (%)
Exhibit 35: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 37: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: Decision framework
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: AstraZeneca - Vendor overview
Exhibit 51: AstraZeneca - Product segments
Exhibit 52: AstraZeneca - Organizational developments
Exhibit 53: AstraZeneca - Geographic focus
Exhibit 54: AstraZeneca - Key offerings
Exhibit 55: Clovis Oncology - Vendor overview
Exhibit 56: Clovis Oncology - Product segments
Exhibit 57: Clovis Oncology - Organizational developments
Exhibit 58: Clovis Oncology - Geographic focus
Exhibit 59: Clovis Oncology - Key offerings
Exhibit 60: F. Hoffmann-La Roche - Vendor overview
Exhibit 61: F. Hoffmann-La Roche - Business segments
Exhibit 62: F. Hoffmann-La Roche - Organizational developments
Exhibit 63: F. Hoffmann-La Roche - Geographic focus
Exhibit 64: F. Hoffmann-La Roche - Segment focus
Exhibit 65: F. Hoffmann-La Roche - Key offerings
Exhibit 66: Spectrum Pharmaceuticals - Vendor overview
Exhibit 67: Spectrum Pharmaceuticals - Business segments
Exhibit 68: Spectrum Pharmaceuticals - Organizational developments
Exhibit 69: Spectrum Pharmaceuticals - Geographic focus
Exhibit 70: Spectrum Pharmaceuticals - Key offerings
Exhibit 71: TESARO - Vendor overview
Exhibit 72: TESARO - Business segments
Exhibit 73: TESARO - Organizational developments
Exhibit 74: TESARO - Geographic focus
Exhibit 75: TESARO - Key offerings
Exhibit 76: Validation techniques employed for market sizing
Exhibit 77: List of abbreviations
PART 02: SCOPE OF THE REPORT
- Preface
- Currency conversion rates for US$
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 05: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
- Market segmentation by type
- Comparison by type
- Epithelial ovarian cancer - Market size and forecast 2018-2023
- Germ cell ovarian cancer - Market size and forecast 2018-2023
- Stromal cell ovarian cancer - Market size and forecast 2018-2023
- Small cell ovarian cancer - Market size and forecast 2018-2023
- Market opportunity by type
PART 09: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
- Market drivers
- Market challenges
- Market trends
- Overview
- Landscape disruption
- Vendors covered
- Vendor classification
- Market positioning of vendors
- AstraZeneca
- Clovis Oncology
- F. Hoffmann-La Roche
- Spectrum Pharmaceuticals
- TESARO
- Research methodology
List of Exhibits
Exhibit 01: Years in consideration
Exhibit 02: Global oncology therapeutics market
Exhibit 03: Segments of global oncology therapeutics market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Pipeline drugs in late-stage clinical trials
Exhibit 07: Market definition - Inclusions and exclusions checklist
Exhibit 08: Market size 2018
Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 11: Five forces analysis 2018
Exhibit 12: Five forces analysis 2023
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2018
Exhibit 19: Type - Market share 2018-2023 (%)
Exhibit 20: Comparison by type
Exhibit 21: Epithelial ovarian cancer - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Epithelial ovarian cancer - Year-over-year growth 2019-2023 (%)
Exhibit 23: Germ cell ovarian cancer - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Germ cell ovarian cancer - Year-over-year growth 2019-2023 (%)
Exhibit 25: Stromal cell ovarian cancer - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Stromal cell ovarian cancer - Year-over-year growth 2019-2023 (%)
Exhibit 27: Small cell ovarian cancer - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Small cell ovarian cancer - Year-over-year growth 2019-2023 (%)
Exhibit 29: Market opportunity by type
Exhibit 30: Customer landscape
Exhibit 31: Market share by geography 2018-2023 (%)
Exhibit 32: Geographic comparison
Exhibit 33: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: North America - Year-over-year growth 2019-2023 (%)
Exhibit 35: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 37: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: Decision framework
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: AstraZeneca - Vendor overview
Exhibit 51: AstraZeneca - Product segments
Exhibit 52: AstraZeneca - Organizational developments
Exhibit 53: AstraZeneca - Geographic focus
Exhibit 54: AstraZeneca - Key offerings
Exhibit 55: Clovis Oncology - Vendor overview
Exhibit 56: Clovis Oncology - Product segments
Exhibit 57: Clovis Oncology - Organizational developments
Exhibit 58: Clovis Oncology - Geographic focus
Exhibit 59: Clovis Oncology - Key offerings
Exhibit 60: F. Hoffmann-La Roche - Vendor overview
Exhibit 61: F. Hoffmann-La Roche - Business segments
Exhibit 62: F. Hoffmann-La Roche - Organizational developments
Exhibit 63: F. Hoffmann-La Roche - Geographic focus
Exhibit 64: F. Hoffmann-La Roche - Segment focus
Exhibit 65: F. Hoffmann-La Roche - Key offerings
Exhibit 66: Spectrum Pharmaceuticals - Vendor overview
Exhibit 67: Spectrum Pharmaceuticals - Business segments
Exhibit 68: Spectrum Pharmaceuticals - Organizational developments
Exhibit 69: Spectrum Pharmaceuticals - Geographic focus
Exhibit 70: Spectrum Pharmaceuticals - Key offerings
Exhibit 71: TESARO - Vendor overview
Exhibit 72: TESARO - Business segments
Exhibit 73: TESARO - Organizational developments
Exhibit 74: TESARO - Geographic focus
Exhibit 75: TESARO - Key offerings
Exhibit 76: Validation techniques employed for market sizing
Exhibit 77: List of abbreviations
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- AstraZeneca
- Clovis Oncology
- F. Hoffmann-La Roche
- Spectrum Pharmaceuticals
- TESARO
Global Ovarian Cancer Drugs Market 2019-2023
The analyst recognizes the following companies as the key players in the global ovarian cancer drugs market: AstraZeneca, Clovis Oncology, F. Hoffmann-La Roche, Spectrum Pharmaceuticals, TESARO.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the research on novel diagnostics methods.”
According to the report, one of the major drivers for this market is the development of a strong pipeline for ovarian cancer is a requirement in the market, which is expected to propel the growth of the market.
Further, the report states that one of the major factors hindering the growth of this market is the lack of expertise and diagnostic methods is expected to hinder the growth of the market.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
The analyst recognizes the following companies as the key players in the global ovarian cancer drugs market: AstraZeneca, Clovis Oncology, F. Hoffmann-La Roche, Spectrum Pharmaceuticals, TESARO.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the research on novel diagnostics methods.”
According to the report, one of the major drivers for this market is the development of a strong pipeline for ovarian cancer is a requirement in the market, which is expected to propel the growth of the market.
Further, the report states that one of the major factors hindering the growth of this market is the lack of expertise and diagnostic methods is expected to hinder the growth of the market.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
- AstraZeneca
- Clovis Oncology
- F. Hoffmann-La Roche
- Spectrum Pharmaceuticals
- TESARO
Note: Product cover images may vary from those shown
LOADING...
